2597933-17-8
Chemical Structure
RBN013209
- CAS No.: 2597933-17-8
- Formula:C19H24N6O3
- Molecular Weight:384.43
IUPAC Name: 2-(1H-imidazol-1-yl)-N-((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide
InChIKey: VQRPLBOIYMUPNF-HDJSIYSDSA-N
SMILES: COCCO[C@@H](CC1)CC[C@H]1NC(C2=C3C(C=CN3)=NC(N4C=CN=C4)=N2)=O
Biological Activity: RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RBN013209 | 98.63% | RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-144988CD38 inhibitor 2 -
Similarity Score 0.73
HY-184493CD38-IN-7 -
Similarity Score 0.54
HY-181543CVN14 -
Similarity Score 0.48
HY-186178CD38-IN-6 -
Similarity Score 0.47
HY-104038RPariceract (Standard) -
Similarity Score 0.45
HY-15798UNC2881 -
Similarity Score 0.44
HY-170303AR ligand-32 -
Similarity Score 0.43
HY-156151CYP51/PD-L1-IN-3 -
Similarity Score 0.43
HY-150757Autophagy-IN-2 -
Explore the MedChemAI to find more analogs
References
- [1]. Laurie B. Schenkel, et al. Heterobicyclic amides as inhibitors of cd38. WO2021021986A1.
- [2]. Shambharkar, et al. Small molecule inhibitor of CD38 modulates its intra-and extracellular functions leading to antitumor activity. Cancer Research 81.13_Supplement (2021): 1344-1344.
- [3]. Huang Y, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024 Feb 20;5(2):101400. [Content Brief]
